Multicentre development and two-stage validation of a patient-reported outcome measure for chronic obstructive pulmonary disease

慢性阻塞性肺疾病患者报告结局指标的多中心开发和两阶段验证

阅读:2

Abstract

Existing patient-reported outcome measures (PROMs) for Chinese patients with chronic obstructive pulmonary disease (COPD) exacerbations have limited conceptual frameworks, uncertain post-COVID-19 validity, and poor clinical interpretability. We conducted a multicenter, two-stage study (pre-pandemic: n = 300; post-pandemic: n = 423) to develop and validate a comprehensive COPD-PROM. The conceptual framework was derived from literature review, expert consultation, and patient interviews. Reliability, validity, and sensitivity were examined, and the minimal clinically important difference (MCID) was established using anchor- and distribution-based methods. The final 52-item COPD-PROM included four domains-physiological, psychological, social, and therapeutic-with Cronbach's α > 0.7 across domains except social. Confirmatory factor analysis indicated acceptable model fit (pre-pandemic: CFI = 0.993, RMSEA = 0.014; post-pandemic: CFI = 0.934, RMSEA = 0.054). The COPD-PROM provides a reliable and interpretable measure of health-related quality of life in COPD, supporting patient-centred assessment and individualized management across healthcare settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。